Latest Period
Q1 2026
Security Snapshot
TENAX THERAPEUTICS, INC. - Common Stock, $0.0001 par value per share (TENX) Institutional Ownership
CUSIP: 88032L605
13F Institutional Holders and Ownership History from Q1 2024 to Q2 2026
Institutions Reporting
79
Shares (Excl. Options)
21,225,929
Price
$15.99
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- TENX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 21,225,929
- Total 13F value
- $339,417,068
- Portfolio coverage rank
- 0%
- Share change
- +14,217,129
- Value change
- +$227,394,441
- Number of holders
- 79
- Shares outstanding
- 39,134,398
- SEC-reported price per share
- $15.98
- Insider filing price
- $15.98
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TENX - TENAX THERAPEUTICS, INC. - Common Stock, $0.0001 par value per share is tracked under CUSIP 88032L605.
- 79 institutions reported positions in Q1 2026.
- 21 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 79 to 22 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $339,417,068 to $43,783,327.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 79 institutions filings for Q1 2026.
Security key
88032L605
Latest holder period
Q1 2026
13F holders
79
13D/G owners
21
CIK / CUSIP context first
Open Q1 2026 holders
TENX full holder history
TENAX THERAPEUTICS, INC. SEC filings
TENAX THERAPEUTICS, INC. company facts
TENAX THERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 88032L605:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
21
Security
TENX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | $42,301,662 | 3,942,373 | FMR LLC | 30 Jun 2026 | |||
| Vestal Point Capital, LP | 9.9% | $18,525,720 | 2,470,096 | Vestal Point Capital, LP | 30 Sep 2024 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $29,248,371 | +$18,881,704 | 1,955,105 | +182% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $28,554,481 | +$17,062,209 | 1,908,722 | +148% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| RTW INVESTMENTS, LP | 9.9% | 0% | $27,939,745 | +$18,201,264 | 1,867,630 | +187% | RTW Investments, LP | 31 Mar 2026 |
| BlackRock, Inc. | 6.4% | $24,856,274 | 1,708,335 | BlackRock, Inc. | 30 Jun 2026 | |||
| Giordano Christopher Thomas | 4.3% | -35% | $27,015,884 | +$6,993,503 | 1,690,606 | +35% | Christopher Thomas Giordano | 31 Jul 2026 |
| PERCEPTIVE ADVISORS LLC | 5.5% | -40% | $21,658,819 | +$13,141,971 | 1,447,782 | +154% | Perceptive Advisors LLC | 31 Mar 2026 |
| Ikarian Capital, LLC | 6.7% | -55% | $13,077,042 | +$2,027,050 | 1,145,100 | +18% | Ikarian Capital, LLC | 31 Mar 2026 |
| Stonepine Capital Management, LLC | 3.7% | $14,588,992 | 975,200 | Stonepine Capital Management, LLC | 31 Mar 2026 | |||
| MILLENNIUM MANAGEMENT LLC | 3.3% | -36% | $9,638,530 | -$5,179,900 | 876,230 | -35% | Millennium Management LLC | 30 Jun 2026 |
| Logos Global Management LP | 3% | -69% | $11,968,000 | +$2,767,600 | 800,000 | +30% | Logos Global Management LP | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 10% | +150% | $4,172,774 | +$3,057,778 | 623,733 | +274% | JANUS HENDERSON GROUP PLC | 28 Nov 2025 |
| MORGAN STANLEY | 3.5% | -61% | $6,812,761 | +$2,147 | 596,564 | +0.03% | Morgan Stanley | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.2% | -80% | $8,781,370 | -$33,721,695 | 586,990 | -79% | T. Rowe Price Associates, Inc. | 31 May 2026 |
| Point72 Asset Management, L.P. | 3.1% | -53% | $7,988,116 | +$1,653,828 | 533,965 | +26% | Point72 Asset Management, L.P. | 31 Mar 2026 |
| INTEGRATED CORE STRATEGIES (US) LLC | 2.1% | -69% | $7,986,979 | +$3,293,848 | 533,889 | +70% | Millennium Management LLC | 31 Mar 2026 |
| Invus Global Management, LLC | 2.5% | -77% | $6,390,029 | 427,141 | 0% | Raymond Debbane | 31 Mar 2026 | |
| Dellora Investments LP | 2.3% | -68% | $5,904,188 | -$95,834 | 394,665 | -1.6% | Dellora Investments LP | 31 Mar 2026 |
| Lind Global Fund II LP | 0.78% | -83% | $3,029,101 | -$3,590,400 | 202,480 | -54% | Lind Global Fund II LP | 31 Mar 2026 |
| S.H.N. Financial Investments Ltd. | 5% | $1,052,814 | 179,050 | S.H.N. Financial Investments Ltd. | 31 Dec 2024 |
As of 31 Mar 2026, 79 institutional investors reported holding 21,225,929 shares of TENAX THERAPEUTICS, INC. - Common Stock, $0.0001 par value per share (TENX). This represents 54% of the company’s total 39,134,398 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.5% | 2,951,116 | 0.01% | $47,189,000 | |
| JANUS HENDERSON GROUP PLC | 4.6% | 1,815,474 | +989% | 0.01% | $29,065,739 |
| Venrock Adviser, LLC | 4.3% | 1,675,262 | 1% | $26,787,439 | |
| PERCEPTIVE ADVISORS LLC | 3.7% | 1,447,782 | +230% | 0.46% | $23,150,034 |
| Ikarian Capital, LLC | 2.6% | 1,017,600 | +5.2% | 2.3% | $16,271,424 |
| Stonepine Capital Management, LLC | 2.5% | 975,200 | +8106% | 14% | $15,593,448 |
| Logos Global Management LP | 1.6% | 625,000 | 0.51% | $9,993,750 | |
| MORGAN STANLEY | 1.5% | 596,564 | +0.03% | 0% | $9,539,058 |
| Velan Capital Investment Management LP | 1.5% | 583,333 | +600% | 5.8% | $9,327,495 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.4% | 540,126 | +548% | 0.01% | $8,636,615 |
| Point72 Asset Management, L.P. | 1.4% | 533,965 | +26% | 0.01% | $8,538,100 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 533,889 | +77% | 0.01% | $8,536,885 |
| ARMISTICE CAPITAL, LLC | 1.2% | 478,827 | 0.25% | $7,656,444 | |
| Siren, L.L.C. | 1.1% | 427,141 | 0% | 0.19% | $6,829,985 |
| TD Asset Management Inc | 1% | 399,184 | 0.01% | $6,382,952 | |
| UBS Group AG | 0.97% | 381,419 | +56323% | 0% | $6,098,890 |
| RTW INVESTMENTS, LP | 0.95% | 370,246 | -2.1% | 0.06% | $5,920,234 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.94% | 366,791 | +4.1% | 0.14% | $5,864,988 |
| MARSHALL WACE, LLP | 0.9% | 352,572 | +18% | 0.01% | $5,637,626 |
| BVF INC/IL | 0.87% | 339,549 | 0% | 0.17% | $5,429,389 |
| GREAT POINT PARTNERS LLC | 0.84% | 327,307 | 1.3% | $5,233,639 | |
| Woodline Partners LP | 0.83% | 323,911 | +126% | 0.02% | $5,179,337 |
| FMR LLC | 0.82% | 322,600 | +129% | 0% | $5,158,374 |
| AMERIPRISE FINANCIAL INC | 0.71% | 279,537 | 0% | $4,469,797 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.67% | 263,421 | 0% | 0% | $4,212,102 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 3,009,163 | $43,783,327 | +$36,127,768 | $14.55 | 22 |
| 2026 Q1 | 21,225,929 | $339,417,068 | +$227,394,441 | $15.99 | 79 |
| 2025 Q4 | 6,948,963 | $84,695,355 | +$29,084,194 | $12.19 | 48 |
| 2025 Q3 | 4,720,738 | $35,929,590 | +$18,970,280 | $7.61 | 34 |
| 2025 Q2 | 2,231,961 | $12,926,914 | +$1,314,380 | $5.76 | 25 |
| 2025 Q1 | 2,006,422 | $13,111,231 | +$4,224,591 | $6.55 | 23 |
| 2024 Q4 | 1,362,190 | $8,426,122 | +$1,144,778 | $6.19 | 21 |
| 2024 Q3 | 1,228,920 | $4,253,022 | +$4,189,827 | $3.46 | 19 |
| 2024 Q2 | 18,829 | $57,207 | +$35,228 | $3.02 | 10 |
| 2024 Q1 | 7,235 | $30,532 | +$30,532 | $4.24 | 9 |